MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

UroGen Pharma Ltd

Отворен

17.2 2.2

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.66

Максимум

17.29

Ключови измерители

By Trading Economics

Приходи

-6.1M

-50M

Продажби

4M

24M

Марж на печалбата

-206.236

Служители

253

EBITDA

-4.5M

-41M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+115.76% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-33M

885M

Предишно отваряне

15

Предишно затваряне

17.2

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

UroGen Pharma Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.06.2025 г., 18:34 ч. UTC

Значими двигатели на пазара

UroGen Pharma Shares Rise on FDA Approval of Bladder Cancer Drug

16.05.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Сравнение с други в отрасъла

Ценова промяна

UroGen Pharma Ltd Прогноза

Ценова цел

By TipRanks

115.76% нагоре

12-месечна прогноза

Среден 36.83 USD  115.76%

Висок 47 USD

Нисък 31 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за UroGen Pharma Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

9.625 / 11.64Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Neutral Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
help-icon Live chat